Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

Neurocognitive decline is a frequent adverse effect of glioblastoma. Antitumor therapies that are efficacious, as measured by traditional endpoints such as objective response (OR) and progression-free survival (PFS), and have beneficial effects on neurocognitive function (NCF) are of clinical benefi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Wefel, Jeffrey S., Cloughesy, Timothy, Zazzali, James L., Zheng, Maoxia, Prados, Michael, Wen, Patrick Y., Mikkelsen, Tom, Schiff, David, Abrey, Lauren E., Yung, W.K. Alfred, Paleologos, Nina, Nicholas, Martin K., Jensen, Randy, Vredenburgh, James, Das, Asha, Friedman, Henry S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2011
Soggetti:
Clinical Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107095/
https://ncbi.nlm.nih.gov/pubmed/21558074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nor024
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi